Albany Molecular Research (AMRI) Tops Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
AMRI Announces Third Quarter 2016 Results
November 8, 2016 7:30 AM ESTALBANY, N.Y., Nov. 8, 2016 /PRNewswire/ --Â AMRI (NASDAQ: AMRI) today reported financial and operating results for the third quarter ended September 30, 2016 and reiterated its outlook for 2016.
Highlights:
Contract revenue of $151.7 million, up 50% from the third quarter 2015 Reported contract margins of 19%; non-GAAP contract margins of 30% Reported basic and diluted EPS $(0.57); non-GAAP diluted EPS of $0.17 Recurring royalty revenue of $1.1 million Reported net loss of $(23.4) million; non-GAAP net income of $7.2 million Adjusted EBITDA of $25.5 million, up 55% from the third quarter 2015 Reaffirms 2016... More